Therapeutics: Lysyl oxidase-like 2 (LOXL2)

Mouse studies suggest inhibiting LOXL2 could help treat breast cancer. In a xenograft mouse model of breast cancer, an anti-LOXL2 antibody decreased tumor growth and the number of lung metastases compared with vehicle. Next steps could include testing LOXL2 inhibition in patient-derived animal models of breast cancer.

Gilead Sciences Inc. has simtuzumab (GS-6624), a humanized mAb against LOXL2, in Phase II testing to treat primary sclerosing cholangitis (PSC) and non-alcoholic steatohepatitis (NASH)...